Contrafect appoints Lisa Ricciardi as chief operating officer. Contrafect Corp., the Yonkers-based biotechnology company developing protein and antibody...
10 months ago

ContraFect has revealed its phase 3 clinical trial has failed an interim futility analysis. The inability of the direct lytic agent to beat placebo triggered...
35 months ago

Novel mechanism of action. In July 2020, ContraFect was awarded a grant by the Combating Antibiotic-Resistant Bacteria Biopharmaceutical...
21 months ago

Under the terms of the securities purchase agreement, ContraFect has agreed to issue 128,000 shares of common stock and pre-funded warrants to...
27 months ago

The study will assess the safety, pharmacokinetics and efficacy of intra-articularly administered exebacase in patients with chronic PJI of the knee.
26 months ago

ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 Million ... In consideration for the immediate exercise of the existing...
23 months ago

ContraFect will receive up to $6.94 million in funding to develop their proprietary therapeutic peptides, a potential therapy for cystic...
75 months ago

Six months ago, ContraFect revealed that exebacase had failed an interim futility analysis in a phase 3 clinical trial called DISRUPT. In a new...
30 months ago

SHARE ... AsianScientist (Apr. 29, 2013) – The Zongyi Group of China has invested US$8.6 million into US-based ContraFect Corporation as part of a...
145 months ago

Lysins, phage enzymes that can undermine bacterial cell walls, have enormous potential as therapeutics. They may even race ahead of...
58 months ago